CYGENE LABORATORIES RECEIVES NOTICE OF ALLOWANCE ON NEW SIGNAL AMPLIFICATION TECHNOLOGY FROM U.S. PATENT AND TRADEMARK OFFICE

ARCHIVED 2002–2016: Originally distributed via the eWire press wire service. Preserved as historical record.

SUBSCRIBE/UNSUBSCRIBE |

Conservation & Wildlife

Corporate Responsibility

Science & Technology

Syndication Partners

**************************************************************************

E-WIRE PRESS RELEASE E-WIRE PRESS RELEASE E-WIRE PRESS RELEASE

**************************************************************************

For Immediate Release

CYGENE LABORATORIES RECEIVES NOTICE OF ALLOWANCE ON NEW SIGNAL AMPLIFICATION TECHNOLOGY FROM U.S. PATENT AND TRADEMARK OFFICE

CORAL SPRINGS, FLORIDA, Nov. 18 -/E-Wire/-- CyGene Laboratories, Inc. (OTC BB: CYGE.OB) announced today that its has received notice from the United States Patent and Trademark Office that it has approved and will issue a patent for the company's first generation signal amplification technology. This new technology allows for early detection of infectious diseases and cancers as well as contamination in food, air and water. To date, CyGene has been issued three patents that can be used for highly accurate isolation of DNA and RNA targets and focus on the elimination/reduction of false positive results. The company's new patent is the first in a series of technologies being developed to focus on the elimination/reduction of false negative results.

"With today's patent notification CyGene now has patent protection for two critical components that we believe will enable us to detect contaminants or disease-causing entities early and accurately in any given sample size," said Martin Munzer, Chief Executive Officer, CyGene Laboratories, Inc. "Our technologies currently under development hold significant commercial applications in the areas of early stage disease recognition, identification of bio-chemical warfare agents and even in the detection of prion proteins that cause mad-cow disease."

About CyGene Laboratories CyGene Laboratories, based in Coral Springs, Florida, is dedicated to developing its proprietary genetic profiling and diagnostic testing methods for the medical marketplace, to become a global leader in broad-based biotechnology applications. Since 1995 the company has been developing proprietary and automated DNA and RNA testing systems for the screening, monitoring and diagnosis of human, veterinary and plant diseases. CyGene's Haystack ProcessingÃ platform supports the highest possible levels of sensitivity and specificity available in the field of molecular diagnostics. The company has also developed AGENDAÃ, a proprietary automated genomic analysis platform. Please visit the website at www.cygene.com.

Forward-Looking Statements The statements made in this press release discussing the patent being the first in a series of technologies and the commercial applications of technologies being developed are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Additionally words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, CyGene's raising sufficient funds to support its development, marketing efforts and corporate overhead, its ability to attract technical employees and the ability of CyGene's management to grow its business with limited assistance. CyGene Laboratories has no duty and undertakes no obligation to update such statements. You should independently investigate and fully understand all risks before making investment decisions.

CyGene Laboratories, Inc.

Martin Munzer, (954) 741-7077, ext. 4403, CyGene Laboratories, Inc., 7786 Wiles Road, Coral Springs, Florida 33067

http://www.cygene.com

**************************************************************************

To Transmit Your News Over E-Wire, visit http://www.ewire.com or

call 1-[REDACTED-PHONE]. E-Wire Is Broadcast To Millions Of Readers Worldwide

**************************************************************************